OverviewSuggest Edit

Tosk is a biopharmaceutical company specializing in cancer treatments. It develops the Side Effect Fly technology using drosophila as a model to screen compounds for their potential to prevent the adverse effects of existing cancer therapies. The company also offers the Genetically Modified Fly used to insert human genes into drosophila for use in drug screening.


Latest Updates

Employees (est.) (Mar 2020)14(+17%)

Key People/Management at Tosk

Brian D. Frenzel

Brian D. Frenzel

President and CEO
Harold Crow

Harold Crow

Chairman of the Board
Charles Garvin

Charles Garvin

Stephen Yanofsky

Stephen Yanofsky

VP Research
William A. Garland

William A. Garland

PhD, Vice President, R&D
Show more

Tosk Financials and Metrics

Summary Metrics

Founding Date


Tosk total Funding

$5.5 m

Tosk latest funding size

$5.45 m

Time since last funding

6 years ago
Tosk's latest funding round in July 2014 was reported to be $5.5 m. In total, Tosk has raised $5.5 m
Show all financial metrics

Tosk Online and Social Media Presence

Embed Graph

Tosk Frequently Asked Questions

  • When was Tosk founded?

    Tosk was founded in 1998.

  • Who are Tosk key executives?

    Tosk's key executives are Brian D. Frenzel, Harold Crow and Charles Garvin.

  • How many employees does Tosk have?

    Tosk has 14 employees.

  • Who are Tosk competitors?

    Competitors of Tosk include Northwest Biotherapeutics, Merrimack Pharmaceuticals and Calithera Biosciences.